SECTOR
Aurobindo Pharma’s arm gets ANVISA’s nod for biosimilars manufacturing facility in Hyderabad
Jul-21-2026

Aurobindo Pharma’s wholly owned subsidiary -- CuraTeQ Biologics (CuraTeQ) has received approval from ANVISA (Agencia Nacional de Vigilancia Sanitaria), the National Health Surveillance Agency of Brazil, for its biosimilars manufacturing facility in Hyderabad. 

The facility underwent a GMP inspection by ANVISA from May 11 to May 15, 2026, and the approval was granted following successful completion of the inspection for biological API and sterile products. The scope of the GMP inspection covered four biosimilar products and assessed the mammalian and microbial drug substance manufacturing facility, prefillable syringe and vial filling facility, packaging and labelling facility, QC testing and release laboratories. 

CuraTeQ’s drug substance and drug product GMP facility is already EMA (European Medicines Agency) and WHO certified and the ANVISA approval reaffirms CuraTeQ’s commitment to global regulatory compliance and quality standards. The approval strengthens the company's capability to supply biosimilar products to the Brazilian and broader Latin American markets.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

  RELATED NEWS >>